2. Metabolic Enzyme/Protease
  3. Xanthine Oxidase
  4. Febuxostat

Febuxostat  (Synonyms: TEI 6720; TMX 67)

Cat. No.: HY-14268 Purity: 99.87%
COA
SDS
Handling Instructions Technical Support

Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.

For research use only. We do not sell to patients.

CAS No. : 144060-53-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of Febuxostat:

Febuxostat Related Antibodies

Top Publications Citing Use of Products

    Febuxostat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.

    Febuxostat (25-200 μM; 3 h) pretreatment significantly enhanced the proliferation rate of HK-2 cells after H/R, with concentrations of 100 μM and 200 μM exhibiting the most pronounced effects.

    Febuxostat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.

    Febuxostat (100 μM; 3 h) significantly decreased expression levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in HK-2 cells after H/R.

    Febuxostat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.

    Febuxostat (100 μM; 3 h) markedly reduced ROS levels in HK-2 cells after H/R.

    Febuxostat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.

    Pretreatment with Febuxostat (100 μM; 3 h) significantly reduced the apoptosis rate of HK-2 cells following H/R treatment.

    Febuxostat purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.

    Pretreatment with Febuxostat (100 μM; 3 h) reversed changes induced by H/R treatment, markedly increased Bcl2 expression, and decreased expression of cleaved caspase-3 and Bax in HK-2 cells.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout[1][2][3].

    IC50 & Target

    Ki: 0.6 nM (Xanthine oxidase)[1]
    In Vitro

    Febuxostat displays potent mixed-type inhibition of the activity of purified bovine milk xanthine oxidase, with Ki and Ki' values of 0.6 nM and 3.1 nM respectively, indicating inhibition of both the oxidized and reduced forms of xanthine oxidase[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Febuxostat Related Antibodies
    In Vivo

    Febuxostat (5-6 mg/kg; i.e.; daily for 4 weeks) (fed a high-fructose diet (60% fructose) for 8 wk) significantly reduces lomerular pressure, renal vasoconstriction, and afferent arteriolar area relative to fructose+P rats, and shows no significant effects in rats on a normal diet when febuxostat treatment alone[2].
    Febuxostat (3-4 mg/kg; p.o.; daily for 4 weeks) with oxonic acid (750 mg/kg; oral gavage; daily for 4 weeks) preventes renal injury in 5/6 Nx (5/6 nephrectomy) rats with and without coexisting hyperuricemia[3].
    Febuxostat (2.5 mg/kg; p.o.; daily for 12 weeks) inhibits plaque formation in ApoE / mice and reduces the levels of ROS in the aortic wall of atherosclerotic mice[4].
    Febuxostat (15.6 mg/kg; p.o.; once daily for 21 successive days) shows antidepressant effect by significantly reduces the immobility time in the FST in mouse[5].
    Febuxostat (10 mg/kg; p.o.; daily for 21 days) administration with doxorubicin caused a significant decrease in nephrotoxicity markers and inflammatory mediators, restoration of normal values of oxidative stress biomarkers and hampering the expression of renal caspase-3[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    316.37

    Formula

    C16H16N2O3S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC(COC1=CC=C(C=C1C#N)C2=NC(C)=C(S2)C(O)=O)C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (158.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.1609 mL 15.8043 mL 31.6086 mL
    5 mM 0.6322 mL 3.1609 mL 6.3217 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 5 mg/mL (15.80 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.1609 mL 15.8043 mL 31.6086 mL 79.0214 mL
    5 mM 0.6322 mL 3.1609 mL 6.3217 mL 15.8043 mL
    10 mM 0.3161 mL 1.5804 mL 3.1609 mL 7.9021 mL
    15 mM 0.2107 mL 1.0536 mL 2.1072 mL 5.2681 mL
    20 mM 0.1580 mL 0.7902 mL 1.5804 mL 3.9511 mL
    25 mM 0.1264 mL 0.6322 mL 1.2643 mL 3.1609 mL
    30 mM 0.1054 mL 0.5268 mL 1.0536 mL 2.6340 mL
    40 mM 0.0790 mL 0.3951 mL 0.7902 mL 1.9755 mL
    50 mM 0.0632 mL 0.3161 mL 0.6322 mL 1.5804 mL
    60 mM 0.0527 mL 0.2634 mL 0.5268 mL 1.3170 mL
    80 mM 0.0395 mL 0.1976 mL 0.3951 mL 0.9878 mL
    100 mM 0.0316 mL 0.1580 mL 0.3161 mL 0.7902 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Febuxostat Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Febuxostat144060-53-7TEI 6720 TMX 67TEI6720TEI-6720TMX67TMX 67TMX-67Xanthine OxidaseXOHyperuricemiagoutp-Erkp-mTORmetabolic syndromeInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Febuxostat
    Cat. No.:
    HY-14268
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.